ClinicalTrials.gg
CompletedNCT06025552Updated Sep 27, 2024

Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects

A Phase 1 interventional study of TU7710 and Normal saline in Hemophilia a, Hemophilia B and Blood Coagulation Disorders, sponsored by TiumBio Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by TiumBio Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Hemophilia A with a site in Korea, Republic of — 8 open to participants now, 16 under way, 12 of them phase 3. Hemophilia A · Korea, Republic of.

Enrollment
34th of 39
40 · median 134
Started
2023
with 4 others
Phase 1
3 of 49
none open now
Registered
45th of 49
by date

Among the 49 studies in Hemophilia A with a site in Korea, Republic of, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2023, is one of 3 in phase 1, and was the 45th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 49 studies in Hemophilia A with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 19 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Hemophilia A with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase 1a, double-blind, randomized, placebo- controlled, SAD study to assess safety, tolerability, PK, and PD of TU7710 in warfarin treated healthy male participants.

Read the detailed description

The 40 subjects will be divided into 5 cohorts, and the subjects assigned to each cohort will be randomly assigned with 6 persons receiving TU7710 and 2 persons receiving a placebo for TU7710. Each cohort will proceed in sequence and the next cohort study will be decided by the Safety Monitoring Committee (SMC) .

Subjects will be participated in the study after warfarin anti-coagulation to maintain the INR between 2.00 and 3.00 as a preventive measure for potential thrombosis prior to the IP administration.

03

Conditions studied

  • Hemophilia a
  • Hemophilia B
  • Blood Coagulation Disorders
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥19 and ≤45
  • of ≥18.0 kg/m2 and ≤30.0 kg/m2
  • Body weight of ≥55.0 kg and ≤90.0 kg
  • Provide and willing to comply with study requirements.

Exclusion criteria

Exclusion Criteria:

  • History or at risk of developing diseases related to venous thromboembolic events or has family history of such disease
  • History of major bleeding/traumatic event or major surgery within 6 month
  • History of any other coagulation disorder (such as gastrointestinal bleeding, hemorrhoid hemorrhage)
  • Abnormal coagulation related laboratory abnormal test results, including protein C, protein S, PT,
  • history or current symptoms of gastrointestinal, liver, or renal disease that may affect the pharmacokinetics of the IP
  • History of or are currently with or C (active or carrier state) or (HIV) or syphilis infection.
  • Currently smoking or have smoked within 1 month before IP or positive cotinine results
  • History of alcohol abuse or positive alcohol breath test
  • Excessive caffeine intake within 7 days before IP
  • INR results not between 2.0\~3.0 range after warfarin treatment
  • History of to medicinal product similar to TU7710 active ingredient or
  • Laboratory abnormal test results, such as \<340msec or >450msec (or family history of long QT syndrome), LDL >190mg/dl , Total cholesterol >300mg/dl, triglycerides > 350mg/dl, >1.5*, AST >1.5*ULN, >1.5*ULN
  • Abnormal vital sign SBP >140mmHG, DBP \<90mmHg, heart rate \<40bpm or >85bpm
  • Any medical history that may increase the risk or affect the evaluation of study objectives by participating in this study at the discretion of the investigator. (e.g., neurology or psychiatric history)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TU7710

    TU7710 of escalating 5 doses

    Drug: TU7710

  • Placebo comparator
    Normal Saline (placebo of TU7710)

    Placebo of TU7710 at corresponding TU7710 dose level

    Drug: Normal saline

Interventions

  • DrugTU7710

    In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.

  • DrugNormal saline

    Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.

06

What researchers measure

Primary outcomes

  1. Number and proportion of participants with adverse events

    Number and proportion of participants with adverse events/ adverse reaction /SAE overall and by treatment group

    Time frame: 30 days post-dose

  2. Number of subjects with significant abnormal laboratory values

    Mean with standard deviation, median, maximum, minimum results of laboratory values in each treatment group. The laboratory parameters that will be assessed are clinical chemistry, hematology and urinalysis.

    Time frame: 30 days post-dose

  3. ADA and Neutralizing antibody results

    Incidence of subjects with ADA and Nab positive results

    Time frame: 30 days post-dose

  4. Number of subjects with significant abnormal Electrocardiography (ECG) findings

    Mean with standard deviation, median, maximum, minimum results of ECG results in each treatment group. The ECG parameters that will be assessed are heart rate, PR interval, QRS interval, QT interval, and QTcF interval.

    Time frame: 30 days post-dose

  5. Number of subjects With Significant Abnormal vital sign findings

    Mean with standard deviation, median, maximum, minimum results of vital sign values in each treatment group. The vital signs that will be assessed are body temperature, pulse rate, respiratory rate, and systolic and diastolic blood pressure.

    Time frame: 30 days post-dose

Secondary outcomes

  1. Pharmacokinetics assessment_Maximum concentration

    Maximum plasma VIIa activity level in each dose level

    Time frame: 4 days post-dose

  2. Pharmacokinetics assessment_AUC last

    Area under plasma activity-time curve after TU7710 single administration from time zero to last quantifiable concentration

    Time frame: 4 days post-dose

  3. Pharmacokinetics assessment_AUC inf

    Area Under the Plasma activity-time curve after TU7710 single administration From Time Zero Extrapolated to Infinity

    Time frame: 4 days post-dose

  4. Pharmacokinetics assessment_Clearance

    Clearance after TU7710 single administration

    Time frame: 4 days post-dose

  5. Pharmacokinetics assessment_Volume of distribution

    Volume of distribution after TU7710 single administration

    Time frame: 4 days post-dose

  6. Pharmacokinetics assessment_Dose proportionality

    Regression analysis using the power model between the log-converted Cmax, AUClast, and the log-converted dose can be performed, and each parameter adjusted by dose can be calculated and compared between the dose groups

    Time frame: 4 days post-dose

  7. Pharmacokinetics assessment_Tmax

    Time from administration to maximum plasma VIIa level in each dose level

    Time frame: 4 days post-dose

  8. Pharmacodynamic assessment_INR change from baseline

    INR measurement change from baseline to day 5 in each treatment group and dose level

    Time frame: 5 days post-dose

  9. Pharmacodynamic assessment_PT change from baseline

    PT measurement change from baseline to day 5 in each treatment group and dose level

    Time frame: 5 days post-dose

  10. Pharmacodynamic assessment_aPTT change from baseline

    aPTT measurement change from baseline to day 5 in each treatment group and dose level

    Time frame: 5 days post-dose

  11. Pharmacokinetics assessment_incremental recovery

    Incremental recovery after TU7710 single administration expressed as the ratio of measured peak level against dose per bodyweight

    Time frame: 4 days post-dose

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Aug 2024, 12 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 12 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Sep 6, 2023
StartActual
Aug 2, 2023
Primary completionActual
Aug 21, 2024
CompletionActual
Aug 21, 2024
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06025552
Lead sponsor
TiumBio Co., Ltd.
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Aug 2, 2023
Primary completion
Aug 21, 2024
Completion
Aug 21, 2024
Last update
Sep 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion